% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Galldiks:864681,
      author       = {Galldiks, Norbert and Kocher, Martin and Ceccon, Garry and
                      Werner, Jan-Michael and Brunn, Anna and Deckert, Martina and
                      Pope, Whitney B and Soffietti, Riccardo and Le Rhun, Emilie
                      and Weller, Michael and Tonn, Jörg C and Fink, Gereon R and
                      Langen, Karl-Josef},
      title        = {{I}maging challenges of immunotherapy and targeted therapy
                      in patients with brain metastases: {R}esponse,
                      {P}rogression, and {P}seudoprogression},
      journal      = {Neuro-Oncology},
      volume       = {22},
      number       = {1},
      issn         = {1523-5866},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {FZJ-2019-04375},
      pages        = {17-30},
      year         = {2020},
      abstract     = {The advent of immunotherapy using immune checkpoint
                      inhibitors (ICIs) and targeted therapy (TT) has dramatically
                      improved the prognosis of various cancer types. However,
                      following ICI therapy or TT—either alone (especially ICI)
                      or in combination with radiotherapy—imaging findings on
                      anatomical contrast-enhanced MRI can be unpredictable and
                      highly variable, and are often difficult to interpret
                      regarding treatment response and outcome. This review aims
                      at summarizing the imaging challenges related to TT and ICI
                      monotherapy as well as combined with radiotherapy in
                      patients with brain metastases, and to give an overview on
                      advanced imaging techniques which potentially overcome some
                      of these imaging challenges. Currently, major evidence
                      suggests that imaging parameters especially derived from
                      amino acid PET, perfusion-/diffusion-weighted MRI, or MR
                      spectroscopy may provide valuable additional information for
                      the differentiation of treatment-induced changes from brain
                      metastases recurrence and the evaluation of treatment
                      response.},
      cin          = {INM-3 / INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31437274},
      UT           = {WOS:000522635600005},
      doi          = {10.1093/neuonc/noz147},
      url          = {https://juser.fz-juelich.de/record/864681},
}